◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Linical Co., Ltd. (2183) Financial History

Name: Linical Co., Ltd. (2183) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Linical Co., Ltd. (2183) operates in the Biotechnology industry and is headquartered in Osaka, Japan with about 577 employees. Its market capitalization is roughly JPY 5 billion. In the fiscal year ended 2026-03-31, 2183 reported JPY 8.7B in revenue and (JPY 3.3B) in net income.

Linical Co., Ltd., a global contract research organization, provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug discovery consulting services, such as market analysis and research of products in development, regulatory affairs, and licensing support.

Interactive charts & full statements →

2183 Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	JPY 8.7B	JPY 10.4B	JPY 12.3B	JPY 12.5B	—
Gross Profit	JPY 1.1B	JPY 2.4B	JPY 3.8B	JPY 4.2B	—
Operating Income (EBIT)	(JPY 2.1B)	(JPY 584M)	JPY 726M	JPY 1.3B	—
Net Income	(JPY 3.3B)	(JPY 539M)	JPY 338M	JPY 1.0B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2183 Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(JPY 361M)	(JPY 338M)	(JPY 316M)	(JPY 316M)	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2183 Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Assets	JPY 12.0B	JPY 16.8B	JPY 18.5B	JPY 17.5B
Total Liabilities	JPY 8.0B	JPY 9.5B	JPY 10.3B	JPY 9.9B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2183 viewer.

Other Companies in Biotechnology

DYN · Dyne Therapeutics, Inc. — $5 billion
ACAD · ACADIA Pharmaceuticals Inc. — $5 billion
EWTX · Edgewise Therapeutics, Inc. — $5 billion
MANE · Veradermics, Incorporated — $5 billion
2617 · TransThera Sciences (Nanjing), Inc. — $5 billion
PBLS · Parabilis Medicines, Inc. — $5 billion
1477 · Ocumension Therapeutics — $4 billion
ELVN · Enliven Therapeutics, Inc. — $4 billion

← 2182 All “0-9” companies 2185 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.